{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:44:02Z","timestamp":1792079042882,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.modpat.2026.101084","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:29:03Z","timestamp":1789666143000},"page":"101084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary Large B-Cell Lymphomas of Immune-Privileged Sites With IRF4 Rearrangement: Clinicopathological and Molecular Characterization"],"prefix":"10.1016","volume":"39","author":[{"given":"Yuxiu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binshen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4143-2554","authenticated-orcid":false,"given":"Yingyong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.modpat.2026.101084_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.modpat.2026.101084_bib2","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V96.10.3569","article-title":"Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites","volume":"96","author":"Riemersma","year":"2000","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.modpat.2026.101084_bib3","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/blood.2023020911","article-title":"Primary large B-cell lymphomas of immune-privileged sites","volume":"144","author":"Roschewski","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.modpat.2026.101084_bib4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/bloodadvances.2019000980","article-title":"Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire","volume":"4","author":"Belhouachi","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.modpat.2026.101084_bib5","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/blood.V94.5.1738","article-title":"V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity","volume":"94","author":"Thompsett","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.modpat.2026.101084_bib6","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0002-9440(10)65526-5","article-title":"Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment","volume":"155","author":"Montesinos-Rongen","year":"1999","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-065X.2012.01113.x","article-title":"The diverse roles of IRF4 in late germinal center B-cell differentiation","volume":"247","author":"De Silva","year":"2012","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.modpat.2026.101084_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood.2019002699","article-title":"Distinct molecular profile of IRF4-rearranged large B-cell lymphoma","volume":"135","author":"Ramis-Zaldivar","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.modpat.2026.101084_bib9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/leu.2008.320","article-title":"Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas","volume":"23","author":"Feldman","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.modpat.2026.101084_bib10","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/bloodadvances.2021006034","article-title":"Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements","volume":"6","author":"Frauenfeld","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.modpat.2026.101084_bib11","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3324\/haematol.2012.076851","article-title":"A low-grade B-cell lymphoma with prolymphocytic\/paraimmunoblastic proliferation and IRF4 rearrangement","volume":"98","author":"Takeuchi","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.modpat.2026.101084_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00428-023-03590-x","article-title":"Emerging entities: high-grade\/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP\/SH lymphoma workshop","volume":"483","author":"Quintanilla-Martinez","year":"2023","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70295","article-title":"Biological heterogeneity in adult IRF4-rearranged large B-cell lymphoma: stratification by age and anatomical site","volume":"10","author":"Zhang","year":"2026","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.modpat.2026.101084_bib14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/PAS.0000000000002301","article-title":"Clinicopathological and molecular characteristics of rare EBV-associated diffuse large B-cell lymphoma with IRF4 rearrangement","volume":"48","author":"Zhang","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101084_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12308-023-00556-5","article-title":"\u201cQuadruple-hit\u201d primary testicular diffuse large B-cell lymphoma with MYD88 L265P mutation, IGH::MYC, and IRF4- and BCL6-rearrangements","volume":"16","author":"Bruehl","year":"2023","journal-title":"J Hematop"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.modpat.2026.101084_bib17","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101084_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2353\/jmoldx.2006.050083","article-title":"FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue","volume":"8","author":"Ventura","year":"2006","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.1016\/j.modpat.2026.101084_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijrobp.2022.07.1835","article-title":"Clinical outcome-related cancer pathways and mutational signatures in patients with unresectable esophageal squamous cell carcinoma treated with chemoradiotherapy","volume":"115","author":"Li","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.modpat.2026.101084_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/PAS.0000000000001957","article-title":"Clinicopathologic features and genomic signature of de novo CD5 + diffuse large B-cell lymphoma: a multicenter collaborative study","volume":"46","author":"Sang","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1016\/j.modpat.2026.101084_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70224","article-title":"Clinical impact of BTK inhibitor exposure in LymphGen-defined MCD diffuse large B-cell lymphoma","volume":"44","author":"Jiang","year":"2026","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101084_bib23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.modpat.2026.101084_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.modpat.2026.101084_bib25","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.modpat.2026.101084_bib26","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/neuonc\/noae115","article-title":"Outcomes and relapse patterns in primary central nervous system lymphoma: longitudinal analysis of 559 patients diagnosed from 1983 to 2020","volume":"26","author":"Tringale","year":"2024","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101084_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.modpat.2026.101084_bib28","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101084_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","article-title":"Primary testicular lymphoma","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.modpat.2026.101084_bib30","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2009.22.5896","article-title":"Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab","volume":"27","author":"Gundrum","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2026.101084_bib32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1023\/A:1012224123385","article-title":"Radiation Therapy Group and the Genito-Urinary Group of the French Federation of Cancer Centres. Non-Hodgkin\u2019s lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres","volume":"12","author":"Lagrange","year":"2001","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101084_bib33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00428-019-02698-3","article-title":"Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis","volume":"476","author":"King","year":"2020","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.modpat.2026.101084_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2405019","article-title":"Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell","volume":"22","author":"Montesinos-Rongen","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.modpat.2026.101084_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/00313025.2010.508786","article-title":"Primary central nervous system lymphoma: a clinicopathological study of 75 cases","volume":"42","author":"Preusser","year":"2010","journal-title":"Pathology"},{"issue":"6","key":"10.1016\/j.modpat.2026.101084_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.prp.2017.02.012","article-title":"Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6","volume":"213","author":"Li","year":"2017","journal-title":"Pathol Res Pract"},{"issue":"12","key":"10.1016\/j.modpat.2026.101084_bib37","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/modpathol.3800691","article-title":"Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases","volume":"19","author":"Al-Abbadi","year":"2006","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101084_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101084_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1440-1789.2009.01074.x","article-title":"Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance","volume":"30","author":"Raoux","year":"2010","journal-title":"Neuropathology"},{"issue":"11","key":"10.1016\/j.modpat.2026.101084_bib40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnen\/nlx083","article-title":"MYC\/BCL2 co-expression is a stronger prognostic factor compared with the cell-of-origin classification in primary CNS DLBCL","volume":"76","author":"Shi","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101084_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-013-1169-7","article-title":"Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas","volume":"126","author":"Brunn","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.modpat.2026.101084_bib42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12885-016-2397-8","article-title":"MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.modpat.2026.101084_bib43","doi-asserted-by":"crossref","first-page":"10165","DOI":"10.2147\/OTT.S222189","article-title":"Prevalence and clinical significance of oncogenic CD79B and MYD88 mutations in primary testicular diffuse large B-cell lymphoma: a retrospective study in China","volume":"12","author":"Chen","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"28","key":"10.1016\/j.modpat.2026.101084_bib44","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101084_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/his.15079","article-title":"Clinical boundaries in adult cases of large B cell lymphoma with IRF4 rearrangement","volume":"84","author":"Maguire","year":"2024","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.modpat.2026.101084_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clml.2023.01.003","article-title":"Whole-exome sequencing revealed the mutational profiles of primary central nervous system lymphoma","volume":"23","author":"Zhang","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.modpat.2026.101084_bib47","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"7332","key":"10.1016\/j.modpat.2026.101084_bib48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.modpat.2026.101084_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101119","article-title":"Comparison of differences in transcriptional and genetic profiles between intra-central nervous system and extra-central nervous system large B-cell lymphoma","volume":"60","author":"Wang","year":"2025","journal-title":"Neoplasia"},{"issue":"7277","key":"10.1016\/j.modpat.2026.101084_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.modpat.2026.101084_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100323","article-title":"Genomic profiling of primary diffuse large B-cell lymphoma of the central nervous system suggests novel potential therapeutic targets","volume":"36","author":"Agostinelli","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib52","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.modpat.2026.101084_bib53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","article-title":"Molecular and clinical diversity in primary central nervous system lymphoma","volume":"34","author":"Hern\u00e1ndez-Verdin","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-025-01421-7","article-title":"Genomic landscape and molecular subtypes of primary central nervous system lymphoma","volume":"16","author":"Li","year":"2025","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.modpat.2026.101084_bib55","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.modpat.2026.101084_bib56","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.modpat.2026.101084_bib57","article-title":"Advances in primary large B-cell lymphoma of immune-privileged sites","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.modpat.2026.101084_bib58","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","article-title":"First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial","volume":"29","author":"Vitolo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101084_bib59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2026.101084_bib60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.6004\/jnccn.2020.7667","article-title":"Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma","volume":"18","author":"Holdhoff","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.modpat.2026.101084_bib61","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.21037\/tcr-21-50","article-title":"Bruton\u2019s tyrosine kinase inhibitors in primary central nervous system lymphoma\u2014evaluation of anti-tumor efficacy and brain distribution","volume":"10","author":"Yu","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"5","key":"10.1016\/j.modpat.2026.101084_bib62","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:39Z","timestamp":1792075539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0893395226001274"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101084","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Large B-Cell Lymphomas of Immune-Privileged Sites With IRF4 Rearrangement: Clinicopathological and Molecular Characterization","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101084"}}